Conivaptan HCl (BioDeep_00000399050)
natural product
代谢物信息卡片
Conivaptan HCl (Vaprisol)
化学式: C32H27ClN4O2 (534.1822)
中文名称: 盐酸考尼伐坦
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C(NC1=CC=C(C=C1)C(N2C3=C(C4=C(CC2)N=C(N4)C)C=CC=C3)=O)(C5=C(C=CC=C5)C6=CC=CC=C6)=O.Cl
InChI: 1H
描述信息
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2180 - Vasopressin Antagonist
D045283 - Natriuretic Agents > D065092 - Antidiuretic Hormone Receptor Antagonists
D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents
同义名列表
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:31430
- KEGGdrug: D01236
- PubChem: 216322
- ChEMBL: CHEMBL1201108
- CAS: 168626-94-6
- CAS: 8626-94-6
- MoNA: CCMSLIB00000078445
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Betül Can, Fatih Kar, Ezgi Kar, Mete Özkoç, Hakan Şentürk, Dilek Burukoğlu Dönmez, Güngör Kanbak, İbrahim Özkan Alataş. Conivaptan and Boric Acid Treatments in Acute Kidney Injury: Is This Combination Effective and Safe?.
Biological trace element research.
2022 Aug; 200(8):3723-3737. doi:
10.1007/s12011-021-02977-8. [PMID: 34676519] - Jonathan Urbach, Steven R Goldsmith. Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials.
Therapeutic advances in cardiovascular disease.
2021 Jan; 15(?):1753944720977741. doi:
10.1177/1753944720977741. [PMID: 33435837] - Young-Beom Kim, Won Woo Jung, Seung Won Lee, Xiangyan Jin, Hyung Kyung Kang, Eun-Hwa Hong, Sun Seek Min, Yoon-Sik Kim, Hee Chul Han, Christopher S Colwell, Yang In Kim. Excessive maternal salt intake gives rise to vasopressin-dependent salt sensitivity of blood pressure in male offspring.
Journal of molecular and cellular cardiology.
2021 01; 150(?):12-22. doi:
10.1016/j.yjmcc.2020.09.013. [PMID: 33011158] - Andrija Vidic, Jerrica E Shuster, Zackary D Goff, Anuradha Godishala, Susan M Joseph, John T Chibnall, Paul J Hauptman. Vasopressin antagonism for decompensated right-sided heart failure.
International journal of cardiology.
2019 Jan; 274(?):245-247. doi:
10.1016/j.ijcard.2018.08.036. [PMID: 30193794] - Sunil Bhandari, Alessandro Peri, Iain Cranston, Rachael McCool, Alison Shaw, Julie Glanville, Larisa Petrakova, Karl O'Reilly. A systematic review of known interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia and a meta-analysis of the vaptans.
Clinical endocrinology.
2017 Jun; 86(6):761-771. doi:
10.1111/cen.13315. [PMID: 28214374] - Caroline Der-Nigoghossian, Christine Lesch, Karen Berger. Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients.
Pharmacotherapy.
2017 May; 37(5):528-534. doi:
10.1002/phar.1926. [PMID: 28295447] - Thomas Marbury, Jerry Fox, Byron Kaelin, Leo Pavliv. Pharmacokinetics of conivaptan use in patients with severe hepatic impairment.
Drug design, development and therapy.
2017; 11(?):373-382. doi:
10.2147/dddt.s125459. [PMID: 28243060] - Mingzhu Yang, John Orgah, Jie Zhu, Guanwei Fan, Jihong Han, Xiaoying Wang, Boli Zhang, Yan Zhu. Danhong injection attenuates cardiac injury induced by ischemic and reperfused neuronal cells through regulating arginine vasopressin expression and secretion.
Brain research.
2016 07; 1642(?):516-523. doi:
10.1016/j.brainres.2016.04.046. [PMID: 27107944] - Shin Nakayama, Mahmood Amiry-Moghaddam, Ole Petter Ottersen, Anish Bhardwaj. Conivaptan, a Selective Arginine Vasopressin V1a and V2 Receptor Antagonist Attenuates Global Cerebral Edema Following Experimental Cardiac Arrest via Perivascular Pool of Aquaporin-4.
Neurocritical care.
2016 Apr; 24(2):273-82. doi:
10.1007/s12028-015-0236-4. [PMID: 26732270] - Biff F Palmer, Amy D Rock, Emily J Woodward. Dose comparison of conivaptan (Vaprisol®) in patients with euvolemic or hypervolemic hyponatremia--efficacy, safety, and pharmacokinetics.
Drug design, development and therapy.
2016; 10(?):339-51. doi:
10.2147/dddt.s95326. [PMID: 26848258] - Aslı Tanındı, Hasan Fehmi Töre. [Use of 'Vaptans' in treatment of hyponatremia].
Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
2015 Apr; 43(3):292-301. doi:
10.5543/tkda.2015.71508. [PMID: 25906004] - Emil Zeynalov, Susan M Jones, Jeong-Woo Seo, Lawrence D Snell, J Paul Elliott. Arginine-Vasopressin Receptor Blocker Conivaptan Reduces Brain Edema and Blood-Brain Barrier Disruption after Experimental Stroke in Mice.
PloS one.
2015; 10(8):e0136121. doi:
10.1371/journal.pone.0136121. [PMID: 26275173] - Tess E Lin, Kirkwood F Adams, J Herbert Patterson. Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients.
Heart failure clinics.
2014 Oct; 10(4):607-20. doi:
10.1016/j.hfc.2014.07.009. [PMID: 25217436] - Yasukatsu Izumi, Katsuyuki Miura, Hiroshi Iwao. Therapeutic potential of vasopressin-receptor antagonists in heart failure.
Journal of pharmacological sciences.
2014; 124(1):1-6. doi:
10.1254/jphs.13r13cp. [PMID: 24401675] - Jonathan D Breshears, Bowen Jiang, Nathan C Rowland, Sandeep Kunwar, Lewis S Blevins. Use of conivaptan for management of hyponatremia following surgery for Cushing's disease.
Clinical neurology and neurosurgery.
2013 Nov; 115(11):2358-61. doi:
10.1016/j.clineuro.2013.08.019. [PMID: 24041963] - Mitchell S Buckley, Shardool A Patel, Allison E Hattrup, Nadine H Kazem, Sara C Jacobs, Mark A Culver. Conivaptan for treatment of hyponatremia in neurologic and neurosurgical adults.
The Annals of pharmacotherapy.
2013 Sep; 47(9):1194-200. doi:
10.1177/1060028013503126. [PMID: 24259735] - Ruediger W Lehrich, David I Ortiz-Melo, Mehul B Patel, Arthur Greenberg. Role of vaptans in the management of hyponatremia.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2013 Aug; 62(2):364-76. doi:
10.1053/j.ajkd.2013.01.034. [PMID: 23725974] - Nicole K Littlejohn, Rick B Siel, Pimonrat Ketsawatsomkron, Christopher J Pelham, Nicole A Pearson, Aline M Hilzendeger, Beth A Buehrer, Benjamin J Weidemann, Huiping Li, Deborah R Davis, Anthony P Thompson, Xuebo Liu, Martin D Cassell, Curt D Sigmund, Justin L Grobe. Hypertension in mice with transgenic activation of the brain renin-angiotensin system is vasopressin dependent.
American journal of physiology. Regulatory, integrative and comparative physiology.
2013 May; 304(10):R818-28. doi:
10.1152/ajpregu.00082.2013. [PMID: 23535460] - Michael J Roy, Keith A Erdman, Anura T Abeyratne, Lisa C Plumb, Kenneth Lasseter, Dennis S Riff, James J Keirns. Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.
Clinical pharmacokinetics.
2013 May; 52(5):385-95. doi:
10.1007/s40262-013-0047-8. [PMID: 23456393] - Alessandro Peri. Clinical review: the use of vaptans in clinical endocrinology.
The Journal of clinical endocrinology and metabolism.
2013 Apr; 98(4):1321-32. doi:
10.1210/jc.2012-4082. [PMID: 23401044] - Bruce Friedman, Joshua Cirulli. Hyponatremia in critical care patients: frequency, outcome, characteristics, and treatment with the vasopressin V2-receptor antagonist tolvaptan.
Journal of critical care.
2013 Apr; 28(2):219.e1-12. doi:
10.1016/j.jcrc.2012.06.001. [PMID: 22884529] - Paul E Marik, Racquel Rivera. Therapeutic effect of conivaptan bolus dosing in hyponatremic neurosurgical patients.
Pharmacotherapy.
2013 Jan; 33(1):51-5. doi:
10.1002/phar.1169. [PMID: 23307545] - Manuel Dominguez, Jose A Perez, Chirag B Patel. Efficacy of 3\% saline vs. conivaptan in achieving hyponatremia treatment goals.
Methodist DeBakey cardiovascular journal.
2013 Jan; 9(1):49-53. doi:
10.14797/mdcj-9-1-49. [PMID: 23519387] - Theresa Human, Adaeze Onuoha, Michael Diringer, Rajat Dhar. Response to a bolus of conivaptan in patients with acute hyponatremia after brain injury.
Journal of critical care.
2012 Dec; 27(6):745.e1-5. doi:
10.1016/j.jcrc.2012.03.003. [PMID: 22520494] - John B O'Connell, Addis Alemayehu. Hyponatremia, heart failure, and the role of tolvaptan.
Postgraduate medicine.
2012 Mar; 124(2):29-39. doi:
10.3810/pgm.2012.03.2534. [PMID: 22437213] - Yoko Fujiwara, Akito Tanoue, Gozoh Tsujimoto, Taka-Aki Koshimizu. The roles of V1a vasopressin receptors in blood pressure homeostasis: a review of studies on V1a receptor knockout mice.
Clinical and experimental nephrology.
2012 Feb; 16(1):30-4. doi:
10.1007/s10157-011-0497-y. [PMID: 22038263] - C Urso, G Caimi. [Hyponatremic syndrome].
La Clinica terapeutica.
2012; 163(1):e29-39. doi:
NULL. [PMID: 22362242] - Steven R Goldsmith, David T Gilbertson, Shari A Mackedanz, Suzanne K Swan. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure.
Journal of cardiac failure.
2011 Dec; 17(12):982-9. doi:
10.1016/j.cardfail.2011.08.012. [PMID: 22123359] - Lisa C Costello-Boerrigter, John C Burnett. Controlling the flood gates: vaptans, furosemide and the quest for a renal protective diuresis.
Journal of cardiac failure.
2011 Dec; 17(12):990-2. doi:
10.1016/j.cardfail.2011.10.002. [PMID: 22123360] - Peter A Gross, Andrea Wagner, Guy Decaux. Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet.
Kidney international.
2011 Sep; 80(6):594-600. doi:
10.1038/ki.2011.78. [PMID: 21451459] - Gregory Valania, Manmeet Singh, Mara T Slawsky. Targeting hyponatremia and hemodynamics in acute decompensated heart failure: is there a role for vasopressin antagonists?.
Current heart failure reports.
2011 Sep; 8(3):198-205. doi:
10.1007/s11897-010-0035-3. [PMID: 21046492] - Manouchkathe Cassagnol, Angela O Shogbon, Maha Saad. The therapeutic use of vaptans for the treatment of dilutional hyponatremia.
Journal of pharmacy practice.
2011 Aug; 24(4):391-9. doi:
10.1177/0897190011415686. [PMID: 21813818] - Matthew B Potts, Anthony F DeGiacomo, Lenna Deragopian, Lewis S Blevins. Use of intravenous conivaptan in neurosurgical patients with hyponatremia from syndrome of inappropriate antidiuretic hormone secretion.
Neurosurgery.
2011 Aug; 69(2):268-73. doi:
10.1227/neu.0b013e318218c78f. [PMID: 21792136] - Christopher Galton, Steven Deem, N David Yanez, Michael Souter, Randall Chesnut, Armagan Dagal, Miriam Treggiari. Open-label randomized trial of the safety and efficacy of a single dose conivaptan to raise serum sodium in patients with traumatic brain injury.
Neurocritical care.
2011 Jun; 14(3):354-60. doi:
10.1007/s12028-011-9525-8. [PMID: 21409494] - Rajat Dhar, Theresa Murphy-Human. A bolus of conivaptan lowers intracranial pressure in a patient with hyponatremia after traumatic brain injury.
Neurocritical care.
2011 Feb; 14(1):97-102. doi:
10.1007/s12028-010-9366-x. [PMID: 20440600] - Thomas Mondritzki, Peter Kolkhof, Hani N Sabbah, Mihai Gheorghiade, Chantal Fürstner, Carsten Schmeck, Harald Siedentop, Stefan Schaefer, Hubert Truebel. Differentiation of arginine vasopressin antagonistic effects by selective V2 versus dual V2/V1a receptor blockade in a preclinical heart failure model.
American journal of therapeutics.
2011 Jan; 18(1):31-7. doi:
10.1097/mjt.0b013e3181f890ad. [PMID: 21192248] - Nadia Ferguson-Myrthil. Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan.
Cardiology in review.
2010 Nov; 18(6):313-21. doi:
10.1097/crd.0b013e3181f5b3b7. [PMID: 20926941] - Michael E Sughrue, Michael McDermott, Lewis S Blevins. Extreme correction of hyponatremia in a patient treated with intravenous conivaptan.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia.
2010 Oct; 17(10):1331-4. doi:
10.1016/j.jocn.2010.01.029. [PMID: 20594854] - Andrew M Naidech, James Paparello, Storm M Liebling, Storm M Leibling, Sarice L Bassin, Kimberly Levasseur, Mark J Alberts, Richard A Bernstein, Kenji Muro. Use of Conivaptan (Vaprisol) for hyponatremic neuro-ICU patients.
Neurocritical care.
2010 Aug; 13(1):57-61. doi:
10.1007/s12028-010-9379-5. [PMID: 20568023] - Barry Greenberg. Managing hyponatremia in patients with heart failure.
Journal of hospital medicine.
2010 Jul; 5 Suppl 3(?):S33-9. doi:
10.1002/jhm.792. [PMID: 21157908] - Nathan A Pinner, Carrie S Oliphant, Jack P Hopkins. Use of conivaptan for the treatment of symptomatic hyponatremia in a patient with acute decompensated heart failure.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
2010 Jun; 67(12):1011-5. doi:
10.2146/ajhp090174. [PMID: 20516472] - Carles Villabona. [Vasopressin receptor antagonists: the vaptans].
Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion.
2010 May; 57 Suppl 2(?):41-52. doi:
10.1016/s1575-0922(10)70021-8. [PMID: 21130961] - Gina González Robledo, Diana Silva Cantillo, Josep Comín Colet. [Hyponatremia in heart failure: physiopathology and pharmacological approach].
Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion.
2010 May; 57 Suppl 2(?):10-4. doi:
10.1016/s1575-0922(10)70017-6. [PMID: 21130957] - Juan Carlos Q Velez, Shirley J Dopson, Donna S Sanders, Tracie A Delay, John M Arthur. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2010 May; 25(5):1524-31. doi:
10.1093/ndt/gfp731. [PMID: 20064953] - Timothy Reilly, Michelle R Schork. Vasopressin antagonists: Pharmacotherapy for the treatment of heart failure.
The Annals of pharmacotherapy.
2010 Apr; 44(4):680-7. doi:
10.1345/aph.1m660. [PMID: 20332337] - Robert D Zenenberg, Alessia L Carluccio, Mark A Merlin. Hyponatremia: evaluation and management.
Hospital practice (1995).
2010 Feb; 38(1):89-96. doi:
10.3810/hp.2010.02.283. [PMID: 20469629] - Navneet S Rehsia, Naranjan S Dhalla. Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.
Heart failure reviews.
2010 Jan; 15(1):85-101. doi:
10.1007/s10741-009-9152-z. [PMID: 19763821] - Markus Haass. [Vasopressin receptor antagonists and heart failure].
Therapeutische Umschau. Revue therapeutique.
2009 Nov; 66(11):735-40. doi:
10.1024/0040-5930.66.11.735. [PMID: 19885790] - Jacqueline G O'Leary, Gary L Davis. Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
2009 Oct; 15(10):1325-9. doi:
10.1002/lt.21836. [PMID: 19790137] - Zhongping Lily Mao, Dennis Stalker, James Keirns. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
Clinical therapeutics.
2009 Jul; 31(7):1542-50. doi:
10.1016/j.clinthera.2009.07.011. [PMID: 19695403] - Siva K Kumar, Paul J Mather. AVP receptor antagonists in patients with CHF.
Heart failure reviews.
2009 Jun; 14(2):83-6. doi:
10.1007/s10741-008-9107-9. [PMID: 18766439] - Yukinori Arai, Akira Fujimori, Masao Sasamata, Keiji Miyata. New topics in vasopressin receptors and approach to novel drugs: research and development of conivaptan hydrochloride (YM087), a drug for the treatment of hyponatremia.
Journal of pharmacological sciences.
2009 Jan; 109(1):53-9. doi:
10.1254/jphs.08r17fm. [PMID: 19151543] - Djillali Annane, Guy Decaux, Neila Smith. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia.
The American journal of the medical sciences.
2009 Jan; 337(1):28-36. doi:
10.1097/maj.0b013e31817b8148. [PMID: 19057376] - Theresa Murphy, Rajat Dhar, Michael Diringer. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit.
Neurocritical care.
2009; 11(1):14-9. doi:
10.1007/s12028-008-9179-3. [PMID: 19123060] - Robert W Schrier, Amirali Masoumi, Elwaleed Elhassan. Role of vasopressin and vasopressin receptor antagonists in type I cardiorenal syndrome.
Blood purification.
2009; 27(1):28-32. doi:
10.1159/000167005. [PMID: 19169014] - Steven R Goldsmith, Uri Elkayam, W Herbert Haught, Abhijit Barve, Weizhong He. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study.
Journal of cardiac failure.
2008 Oct; 14(8):641-7. doi:
10.1016/j.cardfail.2008.06.003. [PMID: 18926434] - Pornpimol Rianthavorn, Joan P Cain, Martin A Turman. Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH.
Pediatric nephrology (Berlin, Germany).
2008 Aug; 23(8):1367-70. doi:
10.1007/s00467-008-0809-y. [PMID: 18437428] - Ferenc Laczi. [Etiology, diagnostics and therapy of hyponatremias].
Orvosi hetilap.
2008 Jul; 149(29):1347-54. doi:
10.1556/oh.2008.28409. [PMID: 18617466] - Joseph G Verbalis, David Zeltser, Neila Smith, Abhijit Barve, Masakazu Andoh. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study.
Clinical endocrinology.
2008 Jul; 69(1):159-68. doi:
10.1111/j.1365-2265.2007.03149.x. [PMID: 18034777] - Dimitrios Farmakis, Gerasimos Filippatos, Dimitrios T Kremastinos, Mihai Gheorghiade. Vasopressin and vasopressin antagonists in heart failure and hyponatremia.
Current heart failure reports.
2008 Jun; 5(2):91-6. doi:
10.1007/s11897-008-0015-z. [PMID: 18765079] - Teresa A Schweiger, Martin M Zdanowicz. Vasopressin-receptor antagonists in heart failure.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
2008 May; 65(9):807-17. doi:
10.2146/ajhp070132. [PMID: 18436727] - Pere Ginès, Andrés Cárdenas. The management of ascites and hyponatremia in cirrhosis.
Seminars in liver disease.
2008 Feb; 28(1):43-58. doi:
10.1055/s-2008-1040320. [PMID: 18293276] - Benjamin L Metzger, Maria V DeVita, Michael F Michelis. Observations regarding the use of the aquaretic agent conivaptan for treatment of hyponatremia.
International urology and nephrology.
2008; 40(3):725-30. doi:
10.1007/s11255-008-9353-8. [PMID: 18363040] - Marit D Moen, Gillian M Keating. Intravenous conivaptan.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
2008; 8(5):341-8; discussion 349. doi:
10.2165/00129784-200808050-00006. [PMID: 18828645] - Siva Kumar, Sharon Rubin, Paul J Mather, David J Whellan. Hyponatremia and vasopressin antagonism in congestive heart failure.
Clinical cardiology.
2007 Nov; 30(11):546-51. doi:
10.1002/clc.18. [PMID: 17847041] - Yeong-Hau H Lien, Joseph I Shapiro. Hyponatremia: clinical diagnosis and management.
The American journal of medicine.
2007 Aug; 120(8):653-8. doi:
10.1016/j.amjmed.2006.09.031. [PMID: 17679119] - Waldemar Olszewski, Jerzy Głuszek. [Vasopressin antagonists in treatment of hyponatremia].
Polskie Archiwum Medycyny Wewnetrznej.
2007 Aug; 117(8):356-62. doi:
10.20452/pamw.182. [PMID: 18018383] - Kimberly A Walter. Conivaptan: new treatment for hyponatremia.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
2007 Jul; 64(13):1385-95. doi:
10.2146/ajhp060383. [PMID: 17592003] - David H Ellison, Tomas Berl. Clinical practice. The syndrome of inappropriate antidiuresis.
The New England journal of medicine.
2007 May; 356(20):2064-72. doi:
10.1056/nejmcp066837. [PMID: 17507705] - Gourang P Patel, Robert A Balk. Recognition and treatment of hyponatremia in acutely ill hospitalized patients.
Clinical therapeutics.
2007 Feb; 29(2):211-29. doi:
10.1016/j.clinthera.2007.02.004. [PMID: 17472815] - David Zeltser, Steven Rosansky, Hannes van Rensburg, Joseph G Verbalis, Neila Smith. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
American journal of nephrology.
2007; 27(5):447-57. doi:
10.1159/000106456. [PMID: 17664863] - Farhan Ali, Maya Guglin, Peter Vaitkevicius, Jalal K Ghali. Therapeutic potential of vasopressin receptor antagonists.
Drugs.
2007; 67(6):847-58. doi:
10.2165/00003495-200767060-00002. [PMID: 17428103] - Farhan Ali, M Adnan Raufi, Barbara Washington, Jalal K Ghali. Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].
Cardiovascular drug reviews.
2007; 25(3):261-79. doi:
10.1111/j.1527-3466.2007.00019.x. [PMID: 17919259] - Koh-ichi Wada, Utane Matsukawa, Akira Fujimori, Yukinori Arai, Katsumi Sudoh, Masao Sasamata, Keiji Miyata. A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
Biological & pharmaceutical bulletin.
2007 Jan; 30(1):91-5. doi:
10.1248/bpb.30.91. [PMID: 17202666] - Marta Martín-Llahí, Mónica Guevara, Pere Ginès. Hyponatremia in cirrhosis: clinical features and management.
Gastroenterologie clinique et biologique.
2006 Oct; 30(10):1144-51. doi:
10.1016/s0399-8320(06)73492-3. [PMID: 17075468] - NULL. Conivaptan (Vaprisol) for hyponatremia.
The Medical letter on drugs and therapeutics.
2006 Jun; 48(1237):51-2. doi:
NULL. [PMID: 16785851] - A Greenberg, J G Verbalis. Vasopressin receptor antagonists.
Kidney international.
2006 Jun; 69(12):2124-30. doi:
10.1038/sj.ki.5000432. [PMID: 16672911] - Jalal K Ghali, Michael J Koren, James R Taylor, Esther Brooks-Asplund, Kaisheng Fan, Walker A Long, Neila Smith. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia.
The Journal of clinical endocrinology and metabolism.
2006 Jun; 91(6):2145-52. doi:
10.1210/jc.2005-2287. [PMID: 16522696] - Nasir Z Sulemanjee, Ernst R Schwarz. Conivaptan: a selective vasopressin antagonist.
Drugs of today (Barcelona, Spain : 1998).
2006 Jun; 42(6):379-86. doi:
10.1358/dot.2006.42.6.985639. [PMID: 16845441] - Phuong-Chi T Pham, Phuong-Mai T Pham, Phuong-Thu T Pham. Vasopressin excess and hyponatremia.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2006 May; 47(5):727-37. doi:
10.1053/j.ajkd.2006.01.020. [PMID: 16632011] - Virginie Bernier, Jean-Pierre Morello, Alexandro Zarruk, Nicolas Debrand, Ali Salahpour, Michèle Lonergan, Marie-Françoise Arthus, André Laperrière, Rémi Brouard, Michel Bouvier, Daniel G Bichet. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.
Journal of the American Society of Nephrology : JASN.
2006 Jan; 17(1):232-43. doi:
10.1681/asn.2005080854. [PMID: 16319185] - Koh-ichi Wada, Akira Fujimori, Utane Matsukawa, Yukinori Arai, Katsumi Sudoh, Takeyuki Yatsu, Masao Sasamata, Keiji Miyata. Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure.
European journal of pharmacology.
2005 Jan; 507(1-3):145-51. doi:
10.1016/j.ejphar.2004.11.022. [PMID: 15659304] - James Walter Ferguson, George Therapondos, David E Newby, Peter Clive Hayes. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis.
Clinical science (London, England : 1979).
2003 Jul; 105(1):1-8. doi:
10.1042/cs20030062. [PMID: 12639215] - Guillermo Fernández-Varo, Josefa Ros, Pilar Cejudo-Martín, Carmen Cano, Vicente Arroyo, Francisca Rivera, Juan Rodés, Wladimiro Jiménez. Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites.
Journal of hepatology.
2003 Jun; 38(6):755-61. doi:
10.1016/s0168-8278(03)00116-8. [PMID: 12763368] - Koh-ichi Wada, Atsuo Tahara, Yukinori Arai, Motonori Aoki, Yuichi Tomura, Junko Tsukada, Takeyuki Yatsu. Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction.
European journal of pharmacology.
2002 Aug; 450(2):169-77. doi:
10.1016/s0014-2999(02)02101-5. [PMID: 12206855] - Mareo Naitoh, John Risvanis, Leanne C Balding, Colin I Johnston, Louise M Burrell. Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition.
Cardiovascular research.
2002 Apr; 54(1):51-7. doi:
10.1016/s0008-6363(02)00244-4. [PMID: 12062361] - Mogamat Razeen Davids, Yeouda Edoute, Jean-Pierre Mallie, Daniel G Bichet, Mitchell L Halperin. Body compartment volumes and composition after giving a vasopressin antagonist: changes are revealed by a tonicity balance.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2002 Feb; 17(2):300-3. doi:
10.1093/ndt/17.2.300. [PMID: 11812887] - A Giełdoń, R Kaźmierkiewicz, R Slusarz, J Ciarkowski. Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors.
Journal of computer-aided molecular design.
2001 Dec; 15(12):1085-104. doi:
10.1023/a:1015905822671. [PMID: 12160092] - J E Udelson, W B Smith, G H Hendrix, C A Painchaud, M Ghazzi, I Thomas, J K Ghali, P Selaru, F Chanoine, M L Pressler, M A Konstam. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure.
Circulation.
2001 Nov; 104(20):2417-23. doi:
10.1161/hc4501.099313. [PMID: 11705818] - M Saito, A Tahara, T Sugimoto, K Abe, K Furuichi. Evidence that atypical vasopressin V(2) receptor in inner medulla of kidney is V(1B) receptor.
European journal of pharmacology.
2000 Aug; 401(3):289-96. doi:
10.1016/s0014-2999(00)00465-9. [PMID: 10936486] - A Naito, Y Ohtake, H Hasegaw, A Y Fukaya, T Kurasawa, K Naito, H Matsukawa, T Oguma, Y Ezure, Y Tsuriya, H Tanaka, K Koike, K Shigenobu. Pharmacological profile of VP-343, a novel selective vasopressin V2 receptor antagonist, in rats.
Biological & pharmaceutical bulletin.
2000 Feb; 23(2):182-9. doi:
10.1248/bpb.23.182. [PMID: 10706381] - M Burnier, A F Fricker, D Hayoz, J Nussberger, H R Brunner. Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects.
European journal of clinical pharmacology.
1999 Nov; 55(9):633-7. doi:
10.1007/s002280050685. [PMID: 10638391] - J Risvanis, M Naitoh, C I Johnston, L M Burrell. In vivo and in vitro characterisation of a nonpeptide vasopressin V(1A) and V(2) receptor antagonist (YM087) in the rat.
European journal of pharmacology.
1999 Sep; 381(1):23-30. doi:
10.1016/s0014-2999(99)00530-0. [PMID: 10528130] - T Yatsu, Y Tomura, A Tahara, K Wada, T Kusayama, J Tsukada, T Tokioka, W Uchida, O Inagaki, Y Iizumi, A Tanaka, K Honda. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure.
European journal of pharmacology.
1999 Jul; 376(3):239-46. doi:
10.1016/s0014-2999(99)00379-9. [PMID: 10448882] - Y Tomura, A Tahara, J Tsukada, T Yatsu, W Uchida, Y Iizumi, K Honda. Pharmacological profile of orally administered YM087, a vasopressin antagonist, in conscious rats.
Clinical and experimental pharmacology & physiology.
1999 May; 26(5-6):399-403. doi:
10.1046/j.1440-1681.1999.03045.x. [PMID: 10386228] - A Tahara, Y Tomura, K Wada, T Kusayama, J Tsukada, N Ishii, T Yatsu, W Uchida, A Tanaka. Binding characteristics of YM087, an AVP receptor antagonist, in rhesus monkey liver and kidney membranes.
Peptides.
1998; 19(4):691-6. doi:
10.1016/s0196-9781(98)00005-9. [PMID: 9622024] - A Tahara, Y Tomura, K I Wada, T Kusayama, J Tsukada, M Takanashi, T Yatsu, W Uchida, A Tanaka. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo.
The Journal of pharmacology and experimental therapeutics.
1997 Jul; 282(1):301-8. doi:
NULL. [PMID: 9223568] - T Yatsu, Y Tomura, A Tahara, K Wada, J Tsukada, W Uchida, A Tanaka, T Takenaka. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs.
European journal of pharmacology.
1997 Feb; 321(2):225-30. doi:
10.1016/s0014-2999(96)00940-5. [PMID: 9063692]
